HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

• Conditions: Hiv

• Registration Number: NCT05036811
• Lead Sponsor: Tourcoing Hospital

Brief Summary

Follow-up registry of patients living with HIV who also have various inflammatory and autoimmune pathologies that may require immunosuppressive treatment.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-04
• Study First Submitted: 2021-04-16
• Study Start: 2021-06-07
• Study First Submitted QC: 2021-09-06
• Last Update Submitted: 2021-09-06
• Study First Posted: 2021-09-08
• Last Update Posted: 2021-09-08
• Primary Completion: 2022-12
• Study Completion: 2023-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Patient living with HIV
• Carrier of one or more of the following diseases:

Sarcoidosis Multiple sclerosis Myasthenia gravis Crohn's disease Hemorrhagic rectocolitis Autoimmune hepatitis Arthropathic psoriasis Still's disease, other rheumatoid arthritides, juvenile polyarthritides, Rheumatoid arthritis Vasculitides: periarteritis nodosa and related conditions, other necrotizing vasculopathies (periarteritis nodosa, juvenile periarteritis, Churg-Strauss disease, polyangiitis, Kawasaki disease, Horton's disease, Wegener's disease, thrombotic microangiopathy, Takayashu syndrome, Good-Pasture's syndrome, thrombocytopenic purpura) Lupus Polymyositis or dermatopolymyositis Connectivitis (Behcet's disease, Gougerot-Sjöogren syndrome) Inflammatory spondyloarthropathies (APS, spondyloarthritis, other spondyloarthropathies)

Exclusion Criteria

• Opposition of the person
• Minor patients
• Patients under judicial protection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of patients living with HIV who have an inflammatory or autoimmune disease	At the end of the study an average of 18 months

Secondary Outcome Measures

Name	Time	Method
Evolution of CD4 and HIV viral load	At the end of the study an average of 18 months
Number of patients on immunosuppressive treatment,	At the end of the study an average of 18 months
Occurrence of infectious complications	At the end of the study an average of 18 months
Number of patients on remission	At the end of the study an average of 18 months

Trial Locations

Locations (1)

CH Tourcoing; 🇫🇷 Tourcoing, France